Background: Monocytes significantly contribute to ischemiareperfusion injury and allograft rejection after kidney transplantation. However, the knowledge about the effects of immunosuppressive drugs on monocyte activation is limited. Conventional pharmacokinetic methods for immunosuppressive drug monitoring are not cell type-specific. In this study, phosphorylation of 3 signaling proteins was measured to determine the pharmacodynamic effects of immunosuppression on monocyte activation in kidney transplant patients.
INTRODUCTION
Monocytes and macrophages contribute to the immune responses after kidney transplantation, which include tissue repair after ischemia-reperfusion injury, as well as acute cellular and antibody-mediated allograft rejection. [1] [2] [3] [4] [5] After ischemia-reperfusion injury, monocytes are activated, in particular through their Toll-like receptor-4 and infiltrate the allograft. 6, 7 Directly after transplantation and during acute cellular rejection, recipient monocytes migrate to the site of tissue injury at the graft and differentiate into CD68 + macrophages, where the presence of these macrophages is associated with graft dysfunction. 4, 8 Infiltrating monocytes can differentiate locally into macrophages, which may be polarized into proinflammatory or anti-inflammatory phenotypes. These have previously been indicated as M1 and M2 macrophages, respectively, and these are now recognized as extremes in a wide functional spectrum. [8] [9] [10] Macrophages are key players in the initiation of antidonor responses through their antigen-presenting function and production of cytokines. In addition to their role in acute cellular rejection, these cells are also involved in antibody-mediated rejection. After binding of monocyte Fc-g receptors to donor allo-antibodies, the signal will block apoptosis and cause the accumulation of monocytes at the site of inflammation, where they produce proinflammatory cytokines. [11] [12] [13] [14] Activation of monocytes and macrophages is controlled, among others, by the 3 intracellular signaling molecules p38 mitogen-activated protein kinase (p38MAPK), extracellular signal-regulated kinases 1 and 2 (ERK1/2), and AKT8 virus oncogene cellular homolog (Akt). [15] [16] [17] [18] [19] [20] Phosphorylation of these molecules by upstream kinases in the signaling pathway causes them to act on transcription factors.
Phosphorylation of the MAPK members p38MAPK and ERK will lead to the activation of transcription factors (eg, NFkB, CREB, and ATF-1) that regulate the transcription and translation of several genes involved in cytokine production (eg, TNF-a, IL-1b, and IL-6). In the end, activation of the MAPK pathway will affect many other monocyte functions, such as phagocytosis and differentiation into distinct macrophage activation stages. [21] [22] [23] Similarly, Akt plays a central role in several pathways (PI3K, NFkB, and mTOR) involved in cytokine production, macrophage differentiation, and phagocytosis. [24] [25] [26] After kidney transplantation, most patients are treated with combination immunosuppressive drug therapy consisting of tacrolimus (TAC), mycophenolic acid (MPA), and glucocorticoids to prevent allograft rejection. 27 The effects of these drugs on alloreactive T-cell function have been extensively characterized, but the knowledge of their effect on monocytes is limited. 5 The few in vitro studies that have been conducted in this respect have indicated that TAC and MPA affect cytokine production by monocytes. 28, 29 Furthermore, TAC did not affect phagocytosis or production of IL-1b in vitro, whereas MPA did reduce the production of IL-1b. 30 Given the important role of monocyte/macrophages in the immune responses after kidney transplantation, a deeper understanding of the effect of immunosuppressive drugs on their activation is important. Furthermore, there is an unmet need for laboratory techniques that can reliably measure such effects to guide clinical immunosuppression. The conventional method of therapeutic drug monitoring (TDM) of immunosuppressive drugs is pharmacokinetic monitoring by determining the (predose) concentration of these drugs in whole blood (in case of TAC) or plasma (in case of MPA). This, however, disregards putative differences in individual responsiveness to these agents. Possibly, cell-specific and pharmacodynamic monitoring of the effects of immunosuppressive drug therapy on monocyte signaling pathway activation may be a superior strategy for TDM. [31] [32] [33] [34] To define a new method for monitoring the impact of immunosuppression on monocyte activation, we monitored and quantified the phosphorylation of p38MAPK, ERK, and Akt by phospho-specific flow cytometry, in whole-blood samples of kidney transplant patients before and after transplantation during treatment with TAC, MPA, and glucocorticoids.
MATERIALS AND METHODS

Kidney Transplant Patients
To determine the effect of immunosuppressive drugs on CD14 + monocyte activation, we studied 20 renal transplant patients who were followed during the first 12 months after transplantation. This study was part of a clinical study that was approved by the Medical Ethical Committee of the Erasmus MC, University Medical Center (MEC number 2012-421, EudraCT # 2012-003169-16). 35, 36 All participants gave written consent for collecting their blood samples. Patients were treated with 20 mg basiliximab intravenously (Simulect; Novartis, Basel, Switzerland) on the day of transplantation and on day 4 after transplantation. During the first 3 postoperative days, prednisolone was administered intravenously in a dosage of 100 mg/d. Subsequently, prednisolone was given orally in a dose of 20 mg and tapered to 5 mg/d by month 3. Mycophenolate mofetil (Cellcept; Roche, Basel, Switzerland) was given in a starting dose of 2000 mg/d equally divided in 2 doses, and then adjusted to predose concentrations (target concentration range: 1.5-3.0 mcg/mL). Patients received TAC (Prograf; Astellas Pharma Inc, Tokyo, Japan) from the day of transplantation twice a day with a starting dose of 0.2 mg/kg/d. Thereafter, TAC was adjusted to predose concentrations: 10-15 ng/mL (week 1-2), 8-12 ng/mL (week 3-4), and 5-10 ng/mL (from week 5 onward). Heparin blood samples were collected before transplantation and 4 days, 1 month, and 3, 6, and 12 months after transplantation.
Absolute numbers of CD14 + monocytes were measured with BD multitest 6-color in BD TruCount Tubes (BD Biosciences, San Jose, CA). TAC whole-blood and MPA plasma predose concentrations were determined in EDTA blood samples using the antibody-conjugated magnetic immunoassay on a Dimension Xpand analyzer (Siemens HealthCare Diagnostics Inc, Newark, DE) according to the manufacturer's instructions. The lower and upper limits of quantification of TAC were 1.5 and 30 ng/mL and for MPA 0.5 mcg/mL and 15 mcg/mL, respectively. For TAC, the coefficients of variation (CV) were 15.0%, 8.9%, and 11.2% for the low, middle, and high control samples, respectively. For MPA, the CV were 3.9% and 3.7%, for the low and high controls, respectively. Proficiency samples were obtained from the UK Quality Assessment Scheme (Analytical Services International Ltd, London, United Kingdom), and the laboratory successfully participates in this international proficiency testing scheme.
Whole-Blood Phospho-specific Flow Cytometry
Phosphorylation of p38MAPK, ERK, and Akt was measured in whole-blood samples according to the manufacturer's instructions for phosphoprotein analysis (BD Biosciences; CV: 5.6%) and as described previously. 37, 38 In short, 200 mL heparinized blood was stained for 30 minutes at 378C with fluorescein isothiocyanate-labeled mouse anti-human CD14 (Serotec, Oxford, United Kingdom) and Brilliant Violet 510-labeled mouse anti-human CD3 (Biolegend, San Diego, CA). After 15 minutes of staining, phorbol 12-myristate 13-acetate (PMA)/ionomycin (Sigma-Aldrich, Steinheim, Germany) was added for 15 minutes to activate the blood cells. Applied final concentrations of PMA/ionomycin were 500 ng per mL/5 mcg per mL for samples stained for p38MAPK and Akt, and 100 ng per mL/1 mcg per mL was used for ERK, based on previous titration for optimal detection of phosphorylated protein. Thereafter, cells were fixed for 10 minutes with Lyse/Fix buffer (BD Biosciences). After permeabilization with 90% methanol at 2208C for 30 minutes, intracellular staining was performed with phycoerythrin (PE)-labeled mouse anti-p-p38MAPK (clone pT180/pY182), PE-labeled mouse anti-p-Akt (clone pS473), or AlexaFluor647 (AF647)-labeled mouse anti-p-ERK1/2 (pT202/pY204) mAB (all from BD Biosciences) for 30 minutes at room temperature. Samples were analyzed on a FACS Canto II flow cytometer (BD Biosciences). Isotype controls mouse IgG1-PE (p38MAPK and Akt; Biolegend) and mouse IgG1-AF647 (ERK; Biolegend) were included in separate tubes and served as negative controls. Interday variability of the flow cytometer was corrected by using Cytocalbeads (Thermo Scientific, Fremont, CA) according to the manufacturer's instructions.
Statistical Analysis
The median fluorescence intensity (MFI) was measured for the phosphorylation of p38MAPK, ERK, and Akt, and data analysis was performed with Diva-version 6.0 software (BD Bioscience). MFI values were normalized using Cytocalbeads (Thermo Scientific). Statistical analysis was performed with Graph Pad Prism 5.0 (Graph Pad Software Inc, La Jolla, CA) by using paired and unpaired t-tests (after finding a P value . 0.05 with the Kolmogorov-Smirnov test for normality for the study population). Correlations between drug concentrations and phosphorylation were calculated as the Spearman correlation coefficient. Associations between phosphorylation levels and covariates were tested by linear regression with IBM SPSS statistics software (version 21; IBM Analytics, Chicago, IL). Bonferroni correction was used to correct for multiple testing. A 2-sided P value ,0.05 was considered statistically significant, and for the association calculations, a 2-sided P value ,0.006 was considered statistically significant after Bonferroni correction.
RESULTS
Patient Characteristics
Baseline characteristics of the kidney transplant patients at the time of transplantation are shown in Table 1 . Two patients suffered from an acute T-cell-mediated rejection corresponding to an overall 1-year acute rejection incidence of 10%. The rejections were classified as Banff type 1B and 2A and occurred on postoperative days 152 and 10, respectively. 39, 40 Samples from these patients were excluded for further analysis after the rejection time point. Absolute monocyte counts before and after transplantation were measured. An increase in the absolute monocyte count was measured at day 4 after transplantation (mean increase of 224 monocytes/mL whole blood; P , 0.01), which can be because of the surgical procedure ( Fig. 1A and see Table, Supplemental Digital Content 1, http://links.lww.com/TDM/A192, which represents the absolute monocyte counts and medication overview). At months 1 and 3, the absolute counts were decreased in comparison with the baseline value (P , 0.01 and P , 0.001, respectively), whereas at months 6 and 12, the monocyte numbers recovered to the baseline level. As expected, TAC predose concentrations were higher at day 4 than at the later time points (P , 0.001) with a median concentration of 15.3 ng/mL (9.1-28.4) at day 4 versus 6.8 ng/mL (4.4-13.3) at day 360 ( Fig. 1B and see Table, Supplemental Digital Content 1, http://links.lww. com/TDM/A192, which represents the absolute monocyte counts and medication overview). In contrast to TAC, MPA predose concentrations did not significantly change over time, which reflects TDM and the intention to keep MPA exposure constant (see Table, Supplemental Digital Content 1, http://links.lww.com/TDM/A192, which represents the absolute monocyte counts and medication overview).
Phosphorylation of p38MAPK, ERK, and Akt in Kidney Transplant Patients
To assess the effects of immunosuppression on the potential of monocytes to become activated, the phosphorylation levels of p38MAPK, ERK, and Akt were measured in whole-blood samples from kidney transplant patients either directly or after stimulation with PMA/ionomycin (see Continuous variables are presented as means (6SD) or medians (range) and categorical variables as numbers (plus percentages), unless otherwise specified.
All patients received their first kidney transplant. HLA, human leukocyte antigen; PRA, panel reactive antibodies (current = PRA at time of transplantation, peak = historically highest measured PRA).
In the unstimulated samples (directly analyzed in fresh blood), the baseline phosphorylation levels of p38MAPK, ERK, and Akt were higher before transplantation than for the isotype control (P , 0.001 for all tested proteins) (Fig. 2) . The phosphorylation level of p38MAPK in these samples was significantly lower compared with pretransplant levels at all test days through day 360 (P , 0.01), except at day 90 ( Fig. 2A) . By contrast, the other MAPK member, ERK, showed only an inhibited phosphorylation at day 4 and day 30 (P , 0.05 and P , 0.001, respectively) and a constant phosphorylation pattern between day 90 and day 360 (Fig. 2B) . The MFI values were comparable with the levels before transplantation. The third signaling protein, Akt, showed a decrease in phosphorylation levels at all time points compared with baseline (pretransplantation; P , 0.05) (Fig. 2C) . The strongest reduction was measured at day 30 (P , 0.01).
To determine the effects of immunosuppression on the maximum phosphorylation capacity of each tested signaling protein, whole-blood samples were stimulated with PMA/ ionomycin for 15 minutes. In these stimulated whole-blood samples, the baseline phosphorylation levels of p38MAPK, ERK, and Akt were higher before transplantation than for the isotype control (Fig. 3) . Again, phosphorylation of p38MAPK and Akt was decreased after transplantation compared with pretransplant phosphorylation (Figs. 3A, B) , which was comparable with the results obtained with the directly measured samples. However, p-ERK expression showed only a decrease at day 4 (Fig. 3C) , which was in contrast to the significant decrease observed at both day 4 and day 30 in the unstimulated samples.
One patient, who was diagnosed with acute rejection on day 152, also showed an increase in p-ERK expression over time after stimulation with PMA/ionomycin, whereas this was not seen for the expression of p-p38MAPK or p-Akt [see Figure, Supplemental Digital Content 3, http://links.lww. com/TDM/A194, which shows the phosphorylation measurements for a patient diagnosed with a biopsy-proven acute rejection on day 152 after transplantation (red arrows)].
We also calculated the percentage of phosphorylation reduction (Table 2 ). In line with the absolute data, the decrease of p-p38MAPK was highest at day 360 [36% (SD 6 31%) and 34% (SD 6 28%) for the unstimulated and PMA/ionomycin-stimulated samples, respectively]. At the other time points tested, the decrease was 31% at most. Finally, p-Akt was reduced, with a maximum of 27%, and showed the smallest decrease at day 90 and 180.
Correlations of Monocyte Signaling Protein Phosphorylation with Patient Treatment and Demographics
To determine a putative association between phosphorylation for all tested signaling proteins and the given immunosuppressive therapy, correlations between immunosuppressive drug predose concentrations and MFI levels at day 4 (n = 14) and 360 (n = 19) in the unstimulated samples were calculated (Table 3) . Both p-p38MAPK and p-AKT, but not p-ERK, showed an inverse correlation with TAC at day 4 (r s = 20.65; P , 0.05 and r s = 20.58; P , 0.05, respectively) (see Figure, Supplemental Digital Content 4, http://links. lww.com/TDM/A195, which shows the correlation between p-p38MAPK and p-Akt and TAC predose concentrations at day 4 after transplantation). At day 360, none of the tested signaling proteins was correlated with TAC predose concentrations.
To define whether the demographic parameters were confounding variables in this study, linear regression analysis was performed (see Table, Supplemental Digital Content 5, http://links.lww.com/TDM/A196, which shows the univariate analysis of the association between patient demographic characteristics and signaling protein phosphorylation). After correction for multiple testing, no association between the demographic characteristics of patients and the level of phosphorylation of p38MAPK, ERK, and Akt was found before FIGURE 1. Absolute monocyte numbers and TAC predose concentrations before and after transplantation. A, Absolute monocyte count in patients before and after transplantation measured as the number of CD14 + monocytes/mL whole blood. B, TAC blood predose concentrations within the first year after transplantation. Data are plotted as box and whiskers indicating total range. Target ranges for both drugs are indicated in light gray in the background (n = 20). *P , 0.05, **P , 0.01, and ***P , 0.001. transplantation or 4 and 360 days after transplantation, indicating that these parameters did not confound the results (see Table, Supplemental Digital Content 5, http://links.lww. com/TDM/A196).
DISCUSSION
Monocytes and macrophages are crucial cells in the innate immune response and are involved in the adaptive immune response through antigen presentation after kidney transplantation. 3, 4 In this pilot study, phospho-specific flow cytometry was used to monitor the effects of immunosuppressive drugs on CD14 + monocyte activation by measuring phosphorylation of 3 major signaling molecules: p38MAPK, ERK, and Akt.
Phospho-specific flow cytometry is a relatively novel technique useful for studying the pharmacodynamic effects of immunosuppressive drug combination therapy in wholeblood samples of kidney transplant patients at the singlecell level. [41] [42] [43] In most transplant centers, TDM is performed by measuring immunosuppressive drug blood concentrations. However, this method is not cell type-specific and does not completely reflect the pharmacodynamic effects of immunosuppressants on monocytes and other immune cells. 44 Furthermore, classic, pharmacokinetic TDM of TAC in general is based on predose concentrations that have an imperfect correlation with the area under the concentration versus time curve and do not accurately predict acute rejection. 45, 46 In recent years, several methods for pharmacodynamic TDM have been investigated, including the measurement of FIGURE 2. Unstimulated phosphorylation of intracellular signaling molecules before and after transplantation in CD14 + monocytes. Unstimulated phosphorylation of p38MAPK (A), ERK (B), and Akt (C) in kidney transplant patients before and within 1 year after transplantation compared with isotype controls. Within 1 month after transplantation, phosphorylation of p38MAPK, ERK, and Akt was decreased. After 1 month, only p-p38MAPK and p-Akt showed a decrease compared with the samples before transplantation (n = 20 patients). *P , 0.05, **P , 0.01, and ***P , 0.001.
calcineurin phosphatase activity, cytokine production, and the expression of NFAT-regulated genes. [47] [48] [49] [50] However, until now, these methods have not found their way into routine clinical practice, because of poor correlation with clinical outcomes, controversial data on the correlation with pharmacokinetic parameters, and high interindividual variability. 44 Furthermore, these pharmacodynamic assays were developed to study the effect on T cells, and it is unknown whether these FIGURE 3. PMA/ionomycin-stimulated phosphorylation of signaling molecules in CD14 + monocytes before and within 1 year after transplantation. Blood samples were stimulated with PMA/ionomycin to determine the maximum phosphorylation capacity for each signaling protein in monocytes. Phosphorylation of p38MAPK (A), ERK (B), and Akt (C) was higher compared with the isotype controls. During 1 year after transplantation, p-p38MAPK and p-Akt, but not p-ERK, were decreased, which is in comparison with the unstimulated results (n = 20 patients). *P , 0.05, **P , 0.01, and ***P , 0.001. 31% (616%)** 27% (627%)** 16% (649%) 25% (638%) 13% (626%)* 25% (627%)** Day 360 36% (631%)** 34% (628%)** 16% (661%) 228% (660%) 20% (623%)* 27% (625%)** methods can also be used for studying the effect of immunosuppressants on monocytes.
A correlation between reduction of p-p38MAPK levels in T-cells and TAC blood concentrations after kidney transplantation was previously found with phospho-specific flow cytometry. 37, 51 In this study, CD14 + monocytes from kidney transplant patients showed a decrease in p-p38MAPK and p-Akt with a maximum of 36% and 20%, respectively, as compared to pretransplant levels. These results are in line with previous in vitro findings: healthy control blood samples spiked with TAC showed a maximum p-p38MAPK and p-Akt inhibition in monocytes of 33% and 14%, respectively. 30 In the in vitro study, spiking with TAC did not affect the production of IL-1b or the phagocytosis by monocytes. Only a slight change in monocyte differentiation toward an M2-like phenotype was measured in the presence of high TAC concentrations. 30 In contrast to the reduction of p-p38MAPK and p-Akt, phosphorylation of the other MAPK member, ERK, was only significantly reduced within the first month after transplantation. The maximum decrease at day 4 and day 30 was 39%, indicating a stronger reduction of p-ERK than of p-p38MAPK and p-Akt. Of note, the expression of p-ERK after stimulation increased with time after transplantation in the one patient who was suffering from acute rejection, indicating a potential role for this signaling molecule in acute rejection.
The decreased phosphorylation found for the signaling molecules indicates that the innate immune response of monocytes is not completely inhibited after kidney transplantation. The incomplete inhibition causes a residual monocyte activity that may contribute to immune responses after kidney transplantation, such as chronic antibody-mediated rejection. The residual monocyte activity is reflected in the retained ability of monocytes to produce proinflammatory and anti-inflammatory cytokines after transplantation. 52 Moreover, the PI3K/Akt pathway is the main regulator of cell survival in human monocytes, and decreased activation of this pathway is associated with immunological quiescence after kidney transplantation. 53, 54 It has also been suggested that p-Akt inhibition causes impairment in IL-10 production and upregulation of p-p38MAPK and p-ERK1/2 after transplantation. 16, 55 Furthermore, MAPK pathways are involved in monocyte adhesion (ERK) and chemotaxis (p38MAPK). 56, 57 p-ERK controls the differentiation, survival, and homeostasis of monocytes when the cells are stimulated with a growth or survival factor, such as macrophage colony-stimulating factor, whereas inhibition of p-ERK causes cell apoptosis. 58, 59 Altogether, this shows that monitoring of signaling pathway activation is important to control monocyte-mediated immune responses after transplantation.
Multiple factors can influence signaling protein phosphorylation, including immunosuppressive drugs. TAC showed a significant negative correlation with phosphorylation intensity of p38MAPK and Akt, suggesting that the inhibition of p-p38MAPK and p-Akt is dependent on TAC concentration. However, these correlations were observed only at day 4, when TAC predose concentrations were highest, which is in line with the findings of the previous in vitro study. 30 No other associations were observed between patient demographics and signaling protein phosphorylation, indicating that phospho-specific flow cytometry is a promising tool to detect TAC effects after transplantation.
These data also indicate that TAC has the most important role in the inhibition of intracellular signaling pathways in monocytes within 4 days after transplantation, whereas the inhibition at later time points may be due to the presence of prednisolone in the blood samples. In mouse peritoneal macrophages, the glucocorticoid receptor is involved in the inhibition of p-p38MAPK, whereas p-ERK and p-Akt are not affected by glucocorticoid signaling. 60 This suggests that the given prednisolone doses in this study could inhibit only p-p38MAPK. However, the prednisolone blood concentrations were not measured in this study, and more research is needed to distinguish between the individual effects of glucocorticoids on monocyte intracellular activation pathways.
This study provides preliminary data on the use of phospho-specific flow cytometry for clinical diagnostics. More research is needed to translate the present findings on phosphorylation status into meaningful clinical diagnostics. For example, all tested proteins in this study showed the least percentage of phosphorylation inhibition between day 90 and 180 after transplantation, but it is unknown whether this will also increase the risk of monocyte-mediated rejection. The technique is ready to be used for clinical diagnostics of malignancies in the field of hematology and oncology. 61, 62 However, for daily clinical TDM of immunosuppressive drugs, this technique needs more validation to become a standardized procedure. The labor intensity, reproducibility, and cost-effectiveness of the technique should be established. However, compared with western blotting, phospho-specific flow cytometry is cell-specific and a relatively rapid method to measure cell signaling pathway activation. For example, the turnaround time of the test used in this study is only 4 hours. The next step would be to study the correlation of phosphorylation profiles with pharmacokinetic parameters and to find a threshold of phosphorylation that indicates a risk of rejection. In a future prospective study, blood samples from kidney transplant patients who might develop rejection should be measured, and the predictive value of the phosphorylation status of the different molecules in monocytes-pp38MAPK, p-ERK, and p-Akt-should be assessed. It could also be informative to combine phospho-specific flow cytometry with the measurement of intralymphocytic or tissue TAC concentrations. The latter directly quantifies the TAC concentration in its target compartment and therefore possibly relates [63] [64] [65] [66] [67] It may also be of interest to combine phospho-specific flow cytometry with novel biomarkers such as graft-derived cellfree DNA. Graft-derived cell-free DNA may serve as a "liquid biopsy" in transplantation, although this biomarker requires further validation, and it remains to be determined whether it may aid in improving TDM of TAC and other immunosuppressive drugs. 68, 69 CONCLUSION Phospho-specific flow cytometry is a technique to measure the pharmacodynamic effects of immunosuppressive drug therapy on CD14 + monocytes. The use of this technique demonstrated that monocyte activation pathways are only partially inhibited by TAC, mycophenolate mofetil, and prednisolone combination therapy after kidney transplantation.
